BioPharma

13 August, 2026 | Thursday | News

Datasea Lists NeuroVibe Biofeedback System with US FDA as Class II 510(k)-Exempt Device

Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digital solutions,  announced that Shuhai Jingwei (Shen...

Lab

13 August, 2026 | Thursday | News

Thermo Fisher, Michael J. Fox Foundation Expand Parkinson’s Proteomics Resource with 5,500 Samples

Olink™ Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher Scientific and The Michael J. Fox Foundation expanded ...

BioTech

04 August, 2026 | Tuesday | Interaction

From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC

BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the evolving opportunities and challenges of expanding acr...

Contract Services

12 August, 2026 | Wednesday | News

Merck Expands Singapore BioReliance Lab with First Cell Line Characterisation and GMP NGS Capabilities in Asia Pacific

Expansion adds first BioReliance® Cell Line Characterization and GMP Next-Generation Sequencing in Asia Pacific Enhanced testing capabilities to deliver speed, sensitivity, and sustainability for bi...

Consumer Health

10 August, 2026 | Monday | Opinion

Why Asia Pacific Must Rethink Chronic Care Before the Demographic Tipping Point

Asia Pacific’s ageing economies are entering a more demanding phase of healthcare planning. As populations live longer, the challenge for healthcare systems is no longer only about extending life expectan...

Medtech

13 August, 2026 | Thursday | News

Ommo Technologies Raises Series A to Scale Spatial Intelligence Platform for Physical AI

VMS Group, a global alternative investment specialist, announced that its portfolio company, Ommo Technologies (Ommo), a spatial intelligence technology company, has completed a Series A financing rou...

Cell & Gene

10 August, 2026 | Monday | News

RiboX Secures FDA IND Clearance for World’s First Circular RNA-Based In Vivo CAR-T Therapy

The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the worl...


Biopharma APAC Infomercial

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close